Antibe Therapeutics Inc.
ATBPF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $3 | $4 | $2 |
| G&A Expenses | $2 | $2 | $3 | $2 |
| SG&A Expenses | $2 | $2 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $5 | $6 | $4 |
| Operating Income | -$5 | -$5 | -$6 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$5 | -$6 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$5 | -$6 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.08 | -0.1 | -0.11 | -0.067 |
| % Growth | 20% | 9.1% | -63.2% | – |
| EPS Diluted | -0.08 | -0.1 | -0.11 | -0.067 |
| Weighted Avg Shares Out | 53 | 53 | 53 | 53 |
| Weighted Avg Shares Out Dil | 53 | 53 | 53 | 53 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$5 | -$3 |
| % Margin | – | – | – | – |